Korean Circulation Journal

  • 제53권7호
  • /
  • Pages.472-479
  • /
  • 2023
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Association Between Serum Bilirubin and Atrial Fibrillation: A Mendelian Randomization Study

  • Si-Woo Kim (Chonnam National University Medical School) ;
  • Jung-Ho Yang (Department of Preventive Medicine, Chonnam National University Medical School) ;
  • Sun-Seog Kweon (Department of Preventive Medicine, Chonnam National University Medical School) ;
  • Young-Hoon Lee (Department of Preventive Medicine & Institute of Wonkwang Medical Science, Wonkwang University School of Medicine) ;
  • Seong-Woo Choi (Department of Preventive Medicine, Chosun University Medical School) ;
  • So-Yeon Ryu (Department of Preventive Medicine, Chosun University Medical School) ;
  • Hae-Sung Nam (Department of Preventive Medicine, Chungnam National University Medical School) ;
  • Hye-Yeon Kim (Department of Preventive Medicine, Chonnam National University Medical School) ;
  • Min-Ho Shin (Department of Preventive Medicine, Chonnam National University Medical School)
  • 투고 : 2023.01.02
  • 심사 : 2023.03.08
  • 발행 : 2023.07.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: The association between bilirubin and atrial fibrillation (AF) has been evaluated previously in observational studies but with contradictory results. This study evaluated the causal association between serum bilirubin level and AF using Mendelian randomization (MR) analysis. Methods: This cross-sectional study includes 8,977 participants from the Dong-gu Study. In the observational analysis, multivariate logistic regression was performed to evaluate the association between bilirubin and prevalent AF. To evaluate the causal association between bilirubin and AF, MR analysis was conducted by using the UGT1A1 rs11891311 and rs4148323 polymorphisms as instrumental variables. Results: Elevated serum bilirubin levels were associated with an increased risk for AF in observational analysis (total bilirubin: odds ratio [OR], 1.31; 95% confidence interval [95% CI], 1.15-1.48 per 1 standard deviation [SD]; direct bilirubin: OR, 1.31; 95% CI, 1.18-1.46 per 1 SD), whereas the genetically predicted serum bilirubin levels in MR analysis did not show this association (total bilirubin: OR, 1.02; 95% CI, 0.67-1.53 per 1 SD; direct bilirubin: OR, 1.03; 95% CI, 0.61-1.73 per 1 SD). Conclusions: Genetically predicted bilirubin levels were not associated with prevalent AF. Thus, the observational association between serum bilirubin levels and AF may be noncausal and affected by reverse causality or unmeasured confounding.

키워드

참고문헌

  1. Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J 2018;48:1033-80. 
  2. Jeong JH. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 2005;20:26-30. 
  3. Lee E, Choi EK, Han KD, et al. Mortality and causes of death in patients with atrial fibrillation: A nationwide population-based study. PLoS One 2018;13:e0209687. 
  4. Pathak RK, Abhilash SP, Hendriks JM. A team-based approach toward risk factors of atrial fibrillation. Card Electrophysiol Clin 2021;13:257-62. 
  5. Suh S, Cho YR, Park MK, Kim DK, Cho NH, Lee MK. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One 2018;13:e0193041. 
  6. Choi SW, Lee YH, Kweon SS, et al. Association between total bilirubin and hemoglobin A1c in Korean type 2 diabetic patients. J Korean Med Sci 2012;27:1196-201. 
  7. Sun W, Li H, Wang Z, Wu Y, Du J. Clinical and laboratory biomarkers in paroxysmal atrial fibrillation: a single center cross-sectional study. Contrast Media Mol Imaging 2022;2022:7012377. 
  8. Sun D, Li W, Zheng W, Tan J, Zhang G. Direct bilirubin level is an independent risk factor for atrial fibrillation in thyrotoxic patients receiving radioactive iodine therapy. Nucl Med Commun 2019;40:1289-94. 
  9. Kuwabara M, Niwa K, Nishihara S, et al. Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int J Cardiol 2017;231:137-42. 
  10. Demir M, Demir C, Uyan U, Melek M. The relationship between serum bilirubin concentration and atrial fibrillation. Cardiol Rev 2013;4:186-91. 
  11. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601. 
  12. Kang TW, Kim HJ, Ju H, et al. Genome-wide association of serum bilirubin levels in Korean population. Hum Mol Genet 2010;19:3672-8.
  13. Kweon SS, Shin MH, Jeong SK, et al. Cohort profile: the namwon study and the Dong-gu study. Int J Epidemiol 2014;43:558-67. 
  14. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii. 
  15. Ayer A, Zarjou A, Agarwal A, Stocker R. Heme oxygenases in cardiovascular health and disease. Physiol Rev 2016;96:1449-508. 
  16. Chen SC, Chung FP, Chao TF, et al. A link between bilirubin levels and atrial fibrillation recurrence after catheter ablation. J Chin Med Assoc 2019;82:175-8. 
  17. Lip GY, Prutkin JM. Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm [Internet]. Waltham (MA): UpToDate; 2021 [cited 2022 September 29]. Available from: https://www.uptodate.com/contents/hemodynamic-consequences-of-atrial-fibrillation-and-cardioversion-to-sinus-rhythm.
  18. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol 2011;20:135-42. 
  19. van Kleef LA, Lu Z, Ikram MA, de Groot NM, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: the Rotterdam study. J Hepatol 2022;77:931-8. 
  20. Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 2016;32:3207-9. 
  21. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013;42:1497-501.